From: Anoikis-related signature predicts prognosis and characterizes immune landscape of ovarian cancer
Characteristic | Univariate Analysis | Multivariate Analysis | ||
---|---|---|---|---|
HR (95% CI) | P-value | HR (95% CI) | P-value | |
Age | Â | Â | Â | Â |
 < 55 years | Reference | – | Reference | – |
 ≥ 55 years | 1.052(0.595–1.862) | 0.861 | 1.189(0.652–2.167) | 0.573 |
FIGO stage | Â | Â | Â | Â |
 I–II | Reference | – | Reference | – |
 III–IV | 4.238(1.897–9.471) | 0.001 | 3.873(1.465–10.239) | 0.006 |
Pathology stage | Â | Â | Â | Â |
 I–II | Reference | – | Reference | – |
 III | 0.727(0.413–1.282) | 0.271 | 0.731(0.373–1.431) | 0.360 |
Histology type | Â | 0.850 | Â | 0.589 |
 Serous | Reference | – | Reference | – |
 Mucous | 0.591(0.181–1.932) | 0.384 | 1.902(0.390–9.286) | 0.427 |
 Endometrioid | 0.875(0.341–2.245) | 0.780 | 0.910(0.330–2.510) | 0.855 |
 Other types | 0.977(0.450–2.122) | 0.953 | 1.676(0.679–4.138) | 0.263 |
Tumor diameter | Â | Â | Â | Â |
 < 10 cm | Reference | – | Reference | – |
 ≥ 10 cm | 1.253(0.710–2.211) | 0.437 | 1.483(0.796–2.764) | 0.215 |
Serum CA125 | Â | Â | Â | Â |
 < 35 U/ml | Reference | – | Reference | – |
 ≥ 35 U/ml | 2.680(0.960–7.486) | 0.060 | 1.202(0.304–4.754) | 0.793 |
DAPK1 expression | Â | Â | Â | Â |
 Low (IRS score < 6) | Reference | – | Reference | – |
 High (IRS score ≥ 6) | 5.994(3.290–10.921) | 0.001 | 5.196(2.789–9.681) | 0.001 |